Lood 1999, 94(10):3334?339. Salven P, Orpana A, Teerenhovi L, Joensuu H: Simultaneous elevation in the serum concentrations of your angiogenic development things VEGF and bFGF is definitely an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 individuals. Blood 2000, 96(12):3712?718. Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G: Angiogenic growth components and endostatin in non-Hodgkin’s lymphoma. Br J Haematol 1999, 106(2):504?09. Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, Bairey O: Expression of simple fibroblast growth aspect is related to poor outcome in non-Hodgkin’s lymphoma. Br J Cancer 2002, 86(11):1770?775. Kowalska M, Janina K, Malgorzata F, Beata K, Alicja S, Joanna T, Jan W: Serum VEGF and bFGF levels in patients with Hodgkin’s lymphoma. NOWOTWORY J Oncol 2007, 57(4):179e?82e. Salmivirta M, Heino J, Jalkanen M: Basic fibroblast growth factor-syndecan complicated at cell surface or immobilized to matrix promotes cell development. J Biol Chem 1992, 267(25):17606?7610. Su G, Blaine SA, Qiao D, Friedl A: Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation through FGF2 activation. J Biol Chem 2007, 282(20):14906?4915. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M: Shedding of syndecan-1 and -4 ectodomains is regulated by a number of signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000, 148(four):811?24. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003, 55(1):20?9. Juuti A, Nordling S, Lundin J, Louhimo J, Haglund C: Syndecan-1 expression novel prognostic marker in pancreatic cancer. Oncology 2005, 68(two?):97?06. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, et al: Higher syndecan-1 expression in breast carcinoma is connected to an aggressive phenotype and to poorer prognosis.(R)-3-Amino-1-methyl-piperidine Chemical name Cancer 2003, 98(3):474?83. Vassilakopoulos TP, Kyrtsonis MC, Papadogiannis A, Nadali G, Angelopoulou MK, Tzenou T, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Kalpadakis C, et al: Serum levels of soluble syndecan-1 in Hodgkin’s lymphoma.1450835-21-8 web Anticancer Res 2005, 25(6C):4743?746.PMID:24982871 Sebestyen A, Berczi L, Mihalik R, Paku S, Matolcsy A, Kopper L: Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. Br J Haematol 1999, 104(2):412?19. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA: Serum syndecan-1, simple fibroblast growth issue and osteoprotegerin in myeloma individuals at diagnosis and during the course with the disease. Eur J Haematol 2004, 72(4):252?58. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C: Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004, 67(1):11?eight. Molica S, Vitelli G, Mirabelli R, Digiesu G, Giannarelli D, Cuneo A, Ribatti D, Vacca A: Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with all the extent of angiogenesis and disease-progression risk in early illness. Leuk Lymphoma 2006, 47(six):1034?040. Aref S, Goda T, El-Sherbiny M: Syndecan-1 in many myeloma: partnership to standard prognostic components. Hematology 2003, eight(4):221?28. Joensuu H, Anttonen A, Eriksson M, Makit.